| Name | TH588 |
| Description | TH588 is nudix hydrolase family inhibitor that effectively and selectively engages and inhibits the MTH1(IC50: 5 nM) in cells. |
| In vitro | In mice carrying xenografts with the BRAFV600E mutation, TH588 (30 mg/kg, subcutaneously) reduces tumor growth rates. Additionally, in mice bearing SW480 colon or MCF7 breast cancer xenografts, TH588 (30 mg/kg, subcutaneously) inhibits MTH1, resulting in decreased tumor growth. |
| In vivo | TH588 induces DNA damage in U2OS cells, triggering ATM-p53-mediated DNA repair and apoptotic responses. It exhibits selective cytotoxicity towards U2OS and other cancer cell lines while showing minimal toxicity towards several primary or immortalized cell lines. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 88.33 mg/mL (299.25 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.78 mM), Sonication is recommended.
|
| Keywords | TH-588 | TH588 | TH 588 | RNASynthesis | RNA Synthesis | MTH1 | Inhibitor | inhibit | DNASynthesis | DNA/RNA Synthesis | DNA Synthesis |
| Inhibitors Related | 5-Fluorouracil | Adenine hemisulfate | Rifaximin | Guanidine hydrochloride | Hexane-1,6-diol | Methotrexate disodium | 1,4-Naphthoquinone | Adenine | Carbazole | Thymidine | Docosanoic acid | Usnic Acid |
| Related Compound Libraries | Highly Selective Inhibitor Library | DNA Damage & Repair Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Multi-Target Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library |